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Abstract. We present a framework for characterizing the performance of an experimental imaging technology,
diffuse optical spectroscopic imaging (DOSI), in a 2-year multicenter American College of Radiology Imaging
Network (ACRIN) breast cancer study (ACRIN-6691). DOSI instruments combine broadband frequency-domain
photon migration with time-independent near-infrared (650 to 1000 nm) spectroscopy to measure tissue absorption and reduced scattering spectra and tissue hemoglobin, water, and lipid composition. The goal of ACRIN6691 was to test the effectiveness of optically derived imaging endpoints in predicting the final pathologic
response of neoadjuvant chemotherapy (NAC). Sixty patients were enrolled over a 2-year period at participating
sites and received multiple DOSI scans prior to and during 3- to 6-month NAC. The impact of three sources of
error on accuracy and precision, including different operators, instruments, and calibration standards, was evaluated using a broadband reflectance standard and two different solid tissue-simulating optical phantoms.
Instruments showed <0.0010 mm−1 (10.3%) and 0.06 mm−1 (4.7%) deviation in broadband absorption and
reduced scattering, respectively, over the 2-year duration of ACRIN-6691. These variations establish a useful
performance criterion for assessing instrument stability. The proposed procedures and tests are not limited to
DOSI; rather, they are intended to provide methods to characterize performance of any instrument used in translational optical imaging. © The Authors. Published by SPIE under a Creative Commons Attribution 3.0 Unported License. Distribution or reproduction of this work in whole or in part requires full attribution of the original publication, including its DOI. [DOI: 10.1117/1.JBO.22.12.121604]

Keywords: diffuse optics; frequency-domain photon migration; independent near-infrared spectroscopy; neoadjuvant chemotherapy;
functional imaging.
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1

Introduction

A variety of diffuse optical spectroscopic imaging (DOSI) methods for the detection, diagnosis, and clinical management of
breast cancer are currently under investigation in clinical studies. DOSI, which employs near-infrared light, is a thick-tissue
functional method capable of quantifying tissue oxy- and
deoxy-hemoglobin, water, and bulk lipid concentration.1 Recent
applications of diffuse optical methods in breast cancer include
monitoring chemotherapy2–7 or hormonal therapy,8 assessing
breast density,9–11 identifying tumors in dense breast tissue,12
and differential diagnosis.13–15
In April 2011, we initiated the American College of
Radiology Imaging Network (ACRIN)-6691 trial (ACRIN-6691)
to test the effectiveness of DOSI to predict the final pathologic
response of breast tumors in patients treated with neoadjuvant
(i.e., presurgical) chemotherapy (NAC).5 Sixty breast cancer
patients receiving NAC were measured longitudinally using

*Address all correspondence to: Bruce J. Tromberg, E-mail: bjtrombe@uci.edu

Journal of Biomedical Optics

DOSI in six clinical research centers across the United States:
Dartmouth College, Massachusetts General Hospital (MGH), MD
Anderson Cancer Center (MDACC), University of California
Irvine (UCI), University of California San Francisco (UCSF),
and University of Pennsylvania (Upenn).
Prior to study activation, five identical DOSI platforms were
distributed to all sites, excluding MDACC, which joined the
study about 1.5 years later. An updated, miniaturized version
of the DOSI instrument was delivered to MDACC. To prevent
introducing additional variation, only data from the five identical instruments that were built simultaneously are compared in
this study. Instrument calibration tools consisted of identical
optical reflectance standards and breast tissue-simulating phantoms fabricated from the same batch of polysiloxane materials.
Procedures and methods for instrument quality control, calibration operating procedures, and patient measurement protocols
were adopted and revised from a previous multicenter breast
cancer imaging study established by the National Cancer
Institute (NCI) Network for Translational Research Optical
Imaging.16 These methods were designed to be simple to
perform by any trained operator and incorporate redundant

121604-1

Downloaded From: https://www.spiedigitallibrary.org/journals/Journal-of-Biomedical-Optics on 23 Jul 2019
Terms of Use: https://www.spiedigitallibrary.org/terms-of-use

December 2017

•

Vol. 22(12)

Leproux et al.: Performance assessment of diffuse optical spectroscopic imaging instruments. . .

mechanisms to assure good data quality, such as multiple
calibration steps and premeasurement system checks. The lead
site (UCI) provided all operators with comprehensive training
materials, including standard operating manuals and videos,17
and several on-site measurement training sessions using human
subjects. To ensure a consistently high level of operator performance, we offered support before, during, and after patient measurements and provided operator feedback in response to the
observed data quality. Postcollection, data were sent to the
lead site for quality control and processing using standardized
methods.
To compare longitudinal measurements from multiple
patients across sites, platforms, and operators, we developed
a systematic approach for assessing the impact of three major
potential sources of variability on DOSI accuracy and precision
over the 2-year study duration: (1) calibration phantoms,
(2) instrument performance, and (3) multiple operators. Starting
with the test case of 1 operator running 1 instrument using
1 calibration phantom, we evaluate how each potential source
of error contributes to overall DOSI performance. Results are
presented across the five different sites and three relevant
time frames: the duration of a patient measurement session
(∼1 h), the duration of the chemotherapy treatment (∼4
months), and the entire study time frame (2 years).

2
2.1

Materials and Methods
Diffuse Optical Spectroscopic Imaging
Instrumentation

A description of the basic components of the DOSI instrument
has been previously presented.18,19 Briefly, DOSI consists of
broadband frequency-domain photon migration (FDPM)
combined with broadband time-independent near-infrared spectroscopy (CW-NIRS). This provides absorption and reduced
scattering spectra in centimeter-thick tissues from 650 to
1000 nm. The FDPM component uses six laser diodes (Blue
Sky Research, Sanyo, Mitsubishi) at the wavelengths 660,
680, 785, 810, 830, and 850 nm that are coupled into a fiber
bundle and delivered to a handpiece that contacts the tissue.
The breast is illuminated sequentially by each laser diode,
which is intensity modulated at 601 modulation frequencies
from 50 to 600 MHz. Phase and amplitude are measured
from three averaged frequency sweeps for a total of ∼200 ms
per laser diode. The diffusely reflected scattered light propagates
through tissue and is detected by an avalanche photodiode
(Hamamatsu module C5658) mounted inside a temperaturecontrolled hand-held probe. The CW-NIRS component uses a
high-intensity tungsten–halogen source (Ocean Optics model
HL-2000-HP-FHSA) to illuminate the tissue. The diffusely
scattered broadband light that propagates through the tissue
is detected by a grating-based spectrometer that collects light
from 650 to 1000 nm (1024 pixels, BWTek model 611E).
The FDPM and CW-NIRS sources are coupled by independent
optical fibers mounted into the hand-held probe. The source–
detector separation was 22 mm (phantom measurement) or
28 mm (breast measurement) for both FDPM and CW-NIRS
components with fibers placed in an overlapping geometry.20
A typical DOSI measurement for the Network Analyzerbased instrument used in this study requires a total of 2 to
5 s per scan location and is composed of three averaged
FDPM sweeps of 601 modulation frequencies and time-integrated broadband CW reflectance spectra.
Journal of Biomedical Optics

FDPM and CW-NIRS data are combined using a diffusion
theory model to provide broadband absorption (μa ) and reduced
scattering (μs0 ) spectra from 650 to 1000 nm. In the FDPM measurement, the phase and amplitude of the detected light are
recorded as functions of source modulation frequency and fit
to a diffusive model of light transport with semi-infinite boundary conditions to recover μa and μs0 at each of the six laser
wavelengths. CW-NIRS broadband reflectance spectra were
converted into absolute absorption spectra using two steps.
First, as per Mie scattering theory, the spectral shape of the
reduced scattering spectrum is assumed to follow a power
law of the form μs0 ¼ Aμ−sp , where A is the scatter amplitude
and sp is the scatter power or the exponent of the reduced scattering spectrum. The power-law fit to the FDPM discrete laser
diode spectrum provides a scatter correction for the CW-NIRS
reflectance spectrum. We then fit the CW-NIRS reflectance
intensity at each of the laser diode wavelengths to the reflectance
calculated from the FDPM-measured absolute absorption values. Thus, the CW-NIRS reflectance spectrum intensity is quantitatively scaled using the FDPM discrete μa measurements. The
absolute absorption spectrum is then extracted by fitting the corrected reflectance spectrum to a diffusion reflectance model.18
A picture of the DOSI instrument used in this study is shown
in Fig. 1(a). The calibration tools of the DOSI instrument are
shown in Figs. 1(b) and 1(c). It consists of a solid tissue-simulating phantom [Fig. 1(b)], which is used to measure the FDPM
instrument response function (IRF) (explicitly, phase offsets,
and amplitude scale factors), and a reflectance standard for
the broadband wavelength calibration [Fig. 1(c)]. The FDPM
IRF measurement is similar to “blanking” performed in a conventional spectrophotometer; using a known attenuation (such
as air), one can remove instrument artifacts such as wavelength-dependent detector responses. In the case of the FDPM
calibration, the tissue-simulating phantoms have known μa and
μs0 values, such that the phase and amplitude changes due to
tissue (or sample) can be separated from the IRF. In the case
of the broadband wavelength calibration, a standard spectralon
reflectance standard (Labsphere) is used to correct the wavelength-dependent variations caused by the light source, detector
response, and optical fiber throughput.

2.2

ACRIN-6691 Trial—Protocol and Study Design

The ACRIN-6691 trial was designed to evaluate the sensitivity
of DOSI to monitor and predict the pathologic response of breast
tumors in patients treated with NAC.5 The long-term goal is to
provide oncologists with a simple, risk-free bedside tool that can
be used to inform medical decisions. These include modifying
or adapting the chemotherapy regimen, duration, and timing of
surgery to maximize therapeutic response and minimize unnecessary toxicity.
A total of 60 breast cancer patients receiving NAC were measured longitudinally using the DOSI instrument in six different
clinical sites. The five following sites, Dartmouth, MGH, UCI,
UCSF, and Upenn used identical DOSI instruments. MDACC
joined the study about 1.5 year after its activation and used a
next generation instrument that was excluded from this analysis.
The subjects were measured four times throughout NAC: baseline (pretreatment), early therapy (5 to 10 days after the initiation
of the first cycle of the chemotherapy), midtherapy (halfway
through the therapy protocol), and posttherapy (prior to surgery). For these patients, the typical chemotherapy length is
4 months.
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Fig. 1 (a) DOSI instrument and (b) and (c) illustrate the probe placed on the calibration phantom (FDPM
calibration) and on the reflectance standard (broadband calibration), respectively.

2.3

Solid Phantom and Reflectance
Standard—Calibration and Testing

Each ACRIN site possessed one broadband reflectance standard
and two solid tissue-simulating optical phantoms, Ph-A and
Ph-B. The Ph-A phantoms, fabricated at UCI, were issued
from the same fabrication batch specifically for the purpose
of the ACRIN study. The specifics of these phantoms, including
the fabrication process, have been previously published.21 The
Ph-B phantoms were developed by Institut National d'Optique,
Inc. (Quebec, Canada). The phantoms within a Ph series are
expected to have the same optical properties as they were fabricated from the same batch. All phantoms have similar optical
properties as breast tissue. The Ph-A and Ph-B phantoms were
arbitrarily chosen to calibrate the FDPM instrument response
during patient measurements and used as an additional calibration phantom for instrument testing, respectively. Measuring the
IRF each session corrects any possible IRF changes between
measurements. To determine IRF, the optical properties of
the reference phantom must be known, and these were derived
from comprehensive series of multidistance, multifrequency,
broadband measurements, a standard procedure that, assuming
phantom homogeneity, utilizes the distance-dependent phase
and amplitude behavior to calculate optical properties.21,22
The solid phantoms are contained in a custom-made case, as
shown Fig. 1(b). Figure 1(c) shows the reflectance standard used
to calibrate the broadband part of the instrument. A mask at the
top of the phantom case and the reflectance standard is designed
to limit placement error by helping the operator to repeatedly
position the probe on the same location.21
Journal of Biomedical Optics

Three sets of three calibration measurements using the two
phantoms and the reflectance standard were performed for every
patient measurement. These calibration measurements were
acquired immediately before, midway through, and after each
breast patient measurement. Iterating the three calibration measurements throughout the measurement session serves two purposes: (1) securing a robust, redundant calibration dataset and
(2) assessing instrument performance throughout the session by
monitoring the optical properties of a fixed phantom over time.

2.4

Data Analysis

Several phantom measurement procedures were designed to test
instrument performance. These procedures consisted of repeat
measurements either of the same phantom or of different phantoms and in various conditions. We report the results of these
tests using the standard deviation (Stdev) of these series of
measurements and the normalized standard deviation (NSD),
which is defined as the Stdev/mean and reported in percent (%).
In case of broadband data, we first obtain the Stdev and NSD
at all wavelengths of the spectrum and report their spectral
average, minimum, maximum, and median.

3
3.1

Results
Methodology to Assess Uncertainties for
the ACRIN-6691 Study

Figure 2 presents the overview of the methodology used to
assess the uncertainties in the context of the ACRIN-6691
study. Uncertainties originate from three main sources:
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Table 1 Description of the different tests performed for each condition in the context of the validation and standardization process of the
ACRIN-6691 study. The number of scans refers to independent measurements of combined FDPM and CW-NIRS consisting of multiple
temporal and spectral sweeps and lasting 2 to 5 s per scan (see
Sec. 2.1).
Time
frame

No. of
scans

A1: Placement test over
imaging session duration

1h

9

A2: Instrument stability over
imaging session duration

1h

60

A3: Instrument stability over
chemotherapy duration

4 months

36

B

B1: Instrument stability over
study duration

2 years

150

C

C1: Phantom comparison

1h

18

D

D1: Interinstrument variability
on one phantom

1 week

15

E

E1: Interinstrument variability;
multiple phantoms and
operators

1 week

30

E2: Overall study variability
over study duration

2 years

480

Conditions
A

Fig. 2 Overview of methodology to assess uncertainties.

phantom, instrument, and operator. Factors contributing to each
of these include, but are not limited to, (1) phantom material
consistency, shelf life, and spatial uniformity, (2) instrument
warm up, stability, reproducibility, and environmental effects,
and (3) procedural consistency, probe operation, and positioning
by different operators. To understand the relative contributions
from each of these sources, we grouped the DOSI calibration
data into five main conditions. The variability in calibration
data across all conditions (A through E) in Fig. 2 is potentially
a sum of all these factors.
The first, condition A, examines the DOSI platform performance with one operator, one phantom, and one instrument,
which is the most favorable situation in terms of potential
sources of uncertainty. Conditions, B, C, and D, consecutively,
assess the study uncertainties by varying one of the three test
parameters, operator, phantom, and instrument, respectively,
and holding two parameters constant. For example, condition
B examines multiple operators (N) with one instrument and
one phantom, while C examines multiple phantoms (N) with
one operator and one instrument, etc. Condition E combines
the contribution of all sources to DOSI measurement error by
examining the performance of all instruments, all phantoms
and with several operators. Multiple measurements and time
periods were used to characterize each of the five main test conditions. A brief summary and description of each test for the
five main conditions is provided in Table 1.

(typical time of chemotherapy treatment at UCI). This corresponded to nine scans per time-point, resulting in a total
of 36 scans. Figure 3 and Table 2 provide the resulting deviations in broadband optical properties. They ranged from 0.0002
to 0.0005 mm−1 for absorption and from 0.01 to 0.03 mm−1 for
reduced scattering coefficients. As shown in Fig. 3(a) inset,
the greatest deviation in absorption occurred at day 1 and
did not seem to follow an increasing or decreasing pattern over
time.

3.3
3.2

Condition A: One Operator, One Phantom, and
One Instrument

Placement and short-term instrument stability tests were conducted on the DOSI instrument at UCI using a Ph-A phantom.
For the placement test, test A1, the phantom was measured for
nine consecutive times, removing and replacing the probe
between each measurement over 1 h, which is the typical patient
measurement session duration. For the instrument stability test,
test A2, a Ph-A phantom was measured continuously every
minute over a 1-h period with the probe fixed onto the phantom.
For both the placement and 1-h stability tests, tests A1 and A2,
the broadband deviations were found to be lower than
0.0010 mm−1 for absorption and 0.01 mm−1 for reduced scattering coefficients (data not shown).
Instrument stability was also investigated over a longer time
frame to determine the potential impact of variations over the
course of chemotherapy, test A3. Measurements of a Ph-A phantom using the DOSI instrument at UCI were acquired by the
same operator at the four study time-points over 4 months
Journal of Biomedical Optics

Test description

Condition B: N Operators, One Phantom, and
One Instrument

The instrument stability was investigated on a Ph-A phantom
over the 2-year duration of the study using the DOSI instrument
at UCI, test B1. A total of 150 scans were performed by four
different trained operators on 17 different days during these 2
years. The same Ph-B phantom was used to calibrate the instrument response of all measurements. The resulting deviations in
broadband absorption and reduced scattering are presented in
Table 3 and Fig. 4. The deviations ranged from 0.0002 to
0.0007 mm−1 in absorption and from 0.01 to 0.03 mm−1 in
reduced scattering coefficients.

3.4

Condition C: One Operator, N Phantoms, and
One Instrument

Using the DOSI instrument at UCI, one operator measured each
phantom three times from the series of Ph-A phantoms to validate their uniformity, test C1. The phantoms were manufactured from the same batch and, thus, should have the same
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Fig. 3 Chemotherapy-long stability test of the DOSI instrument at UCI, test A3: broadband, (a) absorption
and (b) reduced scattering, of a Ph-A phantom measured four times (day 1: presurgery, day 16: early
therapy, day 55: midtherapy, and day 126: posttherapy) over a 4-month period. Inset: expanded scale (a).

Table 2 Deviations in broadband absorption and reduced scattering
of a Ph-A phantom when measured four times over 4 months using
the DOSI instrument at UCI.
μa (mm−1 )

μs0 (mm−1 )

Test A3

Stdev

NSD (%)

Stdev

NSD (%)

Spectral average

0.0003

4.8

0.02

1.7

Spectral min

0.0002

2.4

0.01

1.5

Spectral max

0.0005

8.3

0.03

2.1

Spectral median

0.0003

4.3

0.02

1.6

3.5

Table 3 Deviations over 2 years in broadband absorption and
reduced scattering of a Ph-A phantom measured at UCI by four different operators, test B1.
μa (mm−1 )

optical properties. Figure 5 provides the broadband optical
properties from these compiled measurements, and Table 4 summarizes the Stdevs and coefficient of variation averaged over
the whole spectral range (650 to 1000 nm). The broadband deviations within the series of Ph-A phantoms were found below
0.0003 and 0.01 mm−1 in absorption and in reduced scattering,
respectively.
Overall, the absorption and reduced scattering coefficients
were found to be similar among a series, which is
consistent with the fact that they were fabricated in the same
batch.

μs0 (mm−1 )

Test B1

Stdev

NSD (%)

Stdev

NSD (%)

Spectral average

0.0004

5.3

0.02

1.8

Spectral min

0.0002

2.2

0.01

1.3

Spectral max

0.0007

8.9

0.03

2.5

Spectral median

0.0003

5.7

0.02

1.7

Condition D: One Operator, One Phantom, and
N Instruments

The optical properties recovered from a Ph-A phantom measured using the different DOSI instruments across sites were
compared. These measurements were performed by a single
operator who traveled to the sites with a Ph-A phantom and
an additional calibration phantom.
Figure 6 presents the recovered optical properties of Ph-A
phantom from all sites. Similar absorption and reduced
scattering coefficients were recovered by all instruments. The
absorption spectra recovered at Upenn showed the largest
disagreement compared to the other sites, specifically below
750 nm. Overall, the broadband deviations in absorption and
in reduced scattering within the different instruments ranged
from <0.0001 to 0.0010 mm−1 and from 0.01 to 0.02 mm−1 ,
respectively (see Table 5).

Fig. 4 Deviations in broadband (a) absorption and (b) reduced scattering of a Ph-A phantom measured
17 times over 2 years at UCI by four different operators, test B1. The black lines show the average
spectra. The gray lines show the range (min/max) of spectra.

Journal of Biomedical Optics
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Fig. 5 (a) Absorption and (b) reduced scattering spectra of the Ph-A phantom series measured by one
operator with a single DOSI instrument, test C1.

Table 4 Deviations in broadband absorption and reduced scattering
within the Ph-A phantom series, test C1.
μa (mm−1 )

μs0 (mm−1 )

μa (mm−1 )

Test C1

Stdev

NSD (%)

Stdev

NSD (%)

Spectral average

0.0002

2.8

0.01

1.2

Spectral min

0.0001

1.2

<0.01

0.8

Spectral max

0.0003

4.7

0.01

1.8

Spectral median

0.0002

2.7

0.01

1.0

3.6

Table 5 Deviations in broadband absorption and reduced scattering
of a Ph-A phantom measured at five research sites by a single operator, test D1.

Condition E: N Operators, N Phantoms, and
N Instruments

The optical properties recovered from the Ph-A phantoms measured at their respective sites by the site-specific operator were
compared, test E1. The deviations between the broadbandmeasured absorption and reduced scattering coefficients of the
Ph-A phantoms range from 0.0001 to 0.0010 mm−1 and from
0.01 to 0.02 mm−1 , respectively, see Table 6. The largest deviations in broadband absorption recovery originate from the lower
wavelength range of the spectra, below 760 nm, see Fig. 7.
As for condition D, this phenomenon is particularly visible for
the data acquired at Upenn.
Last, we compared optical properties recovered from all
Ph-A phantoms measured at their respective sites by the on-site

μs0 (mm−1 )

Test D1

Stdev

NSD (%)

Stdev

NSD (%)

Spectral average

0.0004

6.3

0.01

1.4

Spectral min

<0.0001

0.6

0.01

1.2

Spectral max

0.0010

11.1

0.02

1.8

Spectral median

0.0003

6.8

0.01

1.4

operators throughout the 2-year study duration, test E2. This
corresponded to a total of 480 scans acquired on 58 different
days by 18 different operators on the five different instruments;
the resulting absorption and reduced scattering spectra are
shown in Fig. 8. This situation represents the worst-case scenario in term of uncertainties, as it involved measurements on
multiple Ph-A phantoms, by many different operators, using
multiple instruments, over a 2-year period. Note that different
Ph-B phantoms (the ones specific to the site) were also used
to calibrate the instrument response of these measurements.
The deviations between the broadband-measured absorption
and reduced scattering coefficients of the Ph-A phantoms measured at their sites range from 0.0003 to 0.0010 mm−1 and from
0.02 to 0.06 mm−1 , respectively, see Table 7.

Fig. 6 (a) Broadband absorption and (b) reduced scattering spectra of a single Ph-A phantom measured
at the five research sites by a single operator, test D1.

Journal of Biomedical Optics
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Table 6 Deviations in broadband absorption and reduced scattering
of the Ph-A phantoms when measured at their corresponding ACRIN
site, test E1.
μa (mm−1 )

μs0 (mm−1 )

μa (mm−1 )

Test E1

Stdev

NSD (%)

Stdev

NSD (%)

Spectral average

0.0004

5.3

0.01

Spectral min

0.0001

0.8

Spectral max

0.0010

Spectral median

0.0002

4

Table 7 Deviations in broadband absorption and reduced scattering
of 480 scans of the different Ph-A phantoms measured at their corresponding ACRIN site by 18 operators over 2 years, test E2.
μs0 (mm−1 )

Test E2

Stdev

NSD (%)

Stdev

NSD (%)

1.5

Spectral average

0.0005

7.0

0.03

3.1

0.01

1.4

Spectral min

0.0003

4.1

0.02

2.6

10.8

0.02

1.8

Spectral max

0.0010

10.3

0.06

4.7

5.2

0.01

1.5

Spectral median

0.0004

7.1

0.03

2.9

Discussion

ACRIN-6691 is a multicenter trial of DOSI, an experimental
imaging technology, used longitudinally to measure tumor functional changes during presurgical NAC. Because each patient
measurement lasts up to ∼4 months, and quantitative DOSI endpoints are used to predict the clinical outcome, it is essential
that we develop new methods for assessing overall instrument
accuracy and precision over the entire 2-year study period. As a
result, we have devised a series of standardized tissue phantoms
and procedures for evaluating the impact of different potential
sources of uncertainly in DOSI measurements: variability
between different instruments, operators, and calibration standards (tissue phantoms). These methods are designed to define
the level of accuracy and precision required for a multicenter

study over several clinically relevant time frames: (1) 1 h, corresponding to the duration of a single patient measurement
session, (2) several months, corresponding to the duration of
the chemotherapy treatment, and (3) 2 years, corresponding to
the duration of the study. The uniformity of a set of phantoms
was validated, and the instruments were compared across all
operators and sites. These studies are essential for determining
the origins of DOSI performance variations and understanding
how experimental methods such as DOSI compare to other
radiologic approaches.
During a typical 1-h DOSI imaging session, three sets of
three phantom measurements are acquired: before scanning
the tumor breast, between scanning the tumor and normal
breasts, and after scanning the normal breast. We simulated this
in condition A by removing and replacing the DOSI probe on

Fig. 7 (a) Broadband absorption and (b) reduced scattering spectra of the Ph-A phantoms measured at
their sites, test E1.

Fig. 8 Deviations in (a) broadband absorption and (b) reduced scattering of the Ph-A phantoms measured 480 times over 2 years across the five sites by 18 different operators, test E2. The black line shows
the average spectra. The gray lines show the range (min–max) of spectra.
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the Ph-A phantom nine times over a 1-h period, test A1. DOSI
instrument stability over a typical patient measurement time
frame was also evaluated by measuring a Ph-A phantom
every minute for 1 h using one instrument and one operator,
without removing the probe from the phantom, test A2.
During these two different hour-long tests, the NSDs recovered
for broadband absorption and reduced scattering were found to
be lower than 1.4% and 1.0%, respectively. The DOSI instrument is thus highly stable over the duration of a typical patient
measurement session, and removal/replacement of the probe on
a test object has a negligible impact on optical property measurements of well-defined phantoms. This suggests highly reproducible probe placement on phantoms, good phantom homogeneity,
and appropriate warm-up of the instrument. Similar results were
found for the DOSI instruments at the other sites.21
To assess single instrument performance over the chemotherapy treatment time frame with one operator and one phantom, DOSI instrument stability was tested by measuring a Ph-A
phantom four times over 4 months, test A3. Nine measurements
were acquired at each time-point for a total of 36 phantom
measurements. Over these 4 months, the deviations in broadband absorption and reduced scattering were lower than
0.0005 mm−1 (NSD ¼ 8.3%) and 0.03 mm−1 (NSD ¼ 2.1%),
respectively. There was no increasing or decreasing trend
observed in these deviations over time. This suggests that the
variations observed between these measurements are unlikely
due to a time-related drift of the phantom optical properties
or of the instrument performance. In fact, as shown in the
inset in Fig. 3(a), day 1 is the measurement that contributes
most to the deviation. The origin of this disagreement in the
optical properties measured at day 1 is unknown. It is possible
that this is related to the warm-up of the DOSI instrument
(typically about 15 min). Ambient conditions, such as room
temperature and their impact on instrument noise, were likely
responsible for the rest of the variations at days 16, 55, and 126.
We then explored the performance of the DOSI platform
involving multiple operators, one phantom, and one instrument
(condition B). DOSI instrument stability was tested over the
study time frame by comparing the recovered optical properties
of the calibration measurement on a Ph-A phantom obtained at
all baseline patient measurements performed at UCI with four
different operators. Over a period of 2 years and including 150
phantom scans, the deviations in broadband absorption and
reduced scattering were found to be lower than 0.0007 mm−1
(NSD ¼ 8.9%) and 0.03 mm−1 (NSD ¼ 2.5%), respectively.
These deviations are similar to those observed over 4 months
with a single operator, suggesting that DOSI measurements
are operator independent when performed on stable tissue phantoms. In addition to the causes of variation previously mentioned for the other tests, the shelf life of the phantom may
contribute to these errors.
In condition C, we tested the performance of the DOSI platform involving one operator, multiple phantoms, and one instrument. The uniformity of the series of phantoms (Ph-A) was
assessed at UCI by comparing the average of three measurements on each phantom. The phantom series is expected to
have the same optical properties as it was fabricated from the
same mixture. We obtained averaged deviations in recovered
broadband absorption and reduced scattering under 0.0002
and 0.01 mm−1 , corresponding to NSD of 2.1% and 0.9%,
respectively. Compared to the repeatability measurements
done using only a single phantom (test A1), similar deviations
Journal of Biomedical Optics

were observed in condition C with respect to reduced scattering,
and slightly greater deviations were observed in the absorption
(NSD of 2.1% and 1.4%, for test C1 and A1, respectively). The
silicon material used for fabricating phantoms is viscous before
curing, which could potentially lead to some material inconsistency, resulting in some spatial heterogeneity among phantoms
from the same batch. However, the low deviations observed
within the Ph-A phantoms demonstrate uniformity between
these phantoms fabricated from the same batch.
We then explored the performance of the DOSI platform
involving one operator, one phantom, and all instruments
(condition D). While the primary aim of ACRIN-6691 involves
measuring relative changes in DOSI values during NAC, the
secondary aim involves evaluating absolute values at specific
time-points. It is thus important in the context of a multicenter
study to be able to confidently compare quantitative tissue measurements across all subjects and all sites. The average optical
properties recovered between the different instruments were
compared on a single phantom measured three times at all
sites by a unique operator over a period of 1 week. The observed
deviations between sites on this single phantom were ranged
from 0.0004 to 0.0010 mm−1 (NSD ranging from 0.6% to
11.1%) for the broadband absorption and 0.01 to 0.02 mm−1
(NSD ranging from 1.2% to 1.8%) for the broadband reduced
scattering. These results suggest that all DOSI instruments are
comparable in terms of their ability to recover optical properties.
We then repeated this test by involving multiple operators, all
phantoms, and all instruments (condition E). The interinstrument variability was assessed on the Ph-A phantoms at each
site and measured by the on-site operator. The deviations
between sites using their respective Ph-A phantoms were similar
to the deviations obtained in condition D using a single phantom
and operator: below 0.0010 mm−1 (NSD ¼ 10.8%) for the
broadband absorption and 0.02 mm−1 (NSD ¼ 1.8%) for the
broadband reduced scattering. These results suggest that all
DOSI instruments are comparable in terms of optical property
recovery even when different operators and phantoms are
involved.
Last, we determined the performance of the DOSI platform
involving 18 operators, all phantoms, and all instruments over
the 2-year study duration (condition E). This test consisted of
480 measurements of any of the Ph-A phantoms across 58 different days over 2 years. The resulting deviations were below
0.0010 mm−1 (NSD ¼ 10.3%) for the broadband absorption
and 0.06 mm−1 (NSD ¼ 4.7%) for the broadband reduced scattering. This represents the worst-case scenario in terms of uncertainties as many operators, all phantoms, and all instruments
were involved over a 2-year time frame.
In conditions D and E, the greatest variation between instruments occurred below 760 nm and was particularly noticeable in
the Upenn data. Later experiments suggested that this was due to
a greater-than-expected variation in the spectrometer response
in this spectral region caused by the reflectance calibration
approach. A new spectrometer and calibration method has
already been implemented in the next generation of instruments
to mitigate this variation. We decided to keep the current spectrometers in the five instruments in use until the end of the study
for consistency with already acquired subject data.
Although instrument performance was evaluated in the
context of DOSI technology in ACRIN-6691, this general
framework can be adapted to other experimental imaging
technologies. As shown in Fig. 2, the first step is to identify
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the origin of uncertainties, which can vary depending on the
instrumentation used. These sources of variation must then
be isolated and assessed separately in the context of the
study procedures. After the single sources of variation have
been assessed, their combined effect can be addressed.
Though the details of the tests will vary depending on the imaging technique and the study protocol, the proposed framework
can be broadly used to characterize instrument performance in
translational optical imaging studies as has been extensively
reported in the positron emission tomography community.23,24
In conclusion, we have presented a methodology to assess
performance uncertainties in an experimental imaging technology that was used in quantitative longitudinal measurements of
patients over a 2-year period. The impact of multiple phantoms
and operators, and intra- and interinstrument variability has been
addressed separately and jointly. Using this approach, we have
determined that despite 480 DOSI measurements acquired by 18
operators at five research sites over 2 years (58 measurement
days), the resulting deviations were on average 0.0005 mm−1
(NSD ¼ 7.0%) for the broadband absorption and 0.03 mm−1
(NSD ¼ 3.1%) for the broadband reduced scattering. These
data can be used to identify and minimize sources of error
and potentially improve DOSI sensitivity to small changes in
tumor physiology. In addition, the methodology we describe
can be readily adapted and applied to other experimental imaging technologies undergoing evaluation in multicenter settings.
However, additional analysis is required to assess the precise
relationship between these sources of variation and relevant
clinical decision-making thresholds.
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